CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Safety and tolerability of empagliflozin in patients with type 2 diabetes
DOI 10.1055/s-0036-1580888
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Kohler, A Salsali, S Hantel, G Kim, HJ Woerle, UC Broedl
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aim: To assess the safety and tolerability of empagliflozin using data pooled from Phase I, II and III trials in patients with type 2 diabetes (T2DM). Methods: Pooled safety data were analyzed from patients with T2DM who received placebo (n = 3695), empagliflozin 10 mg (n = 3806) or empagliflozin 25 mg (n = 4782) in Phase I, II and III trials (including extensions). Adverse events (AEs) were assessed descriptively i…
Zitieren
Zitierempfehlung
S Kohler, A Salsali, S Hantel, G Kim, HJ Woerle, UC Broedl (2016) Safety and tolerability of empagliflozin in patients with type 2 diabetes. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0036-1580888
Mit CareLit weiterarbeiten